Skip to content

LEC Proliferation in Vivo and In-vitro

Bilateral and Age-dependent Differences in Posterior Capsule Opacification in Vivo Compared to an In-vitro Mode

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03857685
Enrollment
40
Registered
2019-02-28
Start date
2019-01-01
Completion date
2021-01-01
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posterior Capsule Opacification

Keywords

Lens capsule, Proliferation

Brief summary

Investigate the proliferative capacity of individual lens epithelium capsule specimens in vitro and correlate it to the risk of developing PCO

Detailed description

Cataract, the clouding of the eye's lens, is still the leading cause of blindness worldwide. Until now surgery is the only therapy available for the disease. Cataract surgery is nowadays considered a safe and efficient therapy. However, one of the most frequent complications of cataract surgery is posterior capsule opacification (PCO), which results in diminished postoperative visual acuity. PCO occurs due to a robust wound-healing response, where remaining lens epithelial cells in the capsular bag start to migrate and proliferate. The lens capsule is divided into an anterior, an equatorial, and a posterior region. The anterior and the equatorial region consist of a single layer of cuboidal epithelial cells, whilst the posterior region is formed of fibers. In the adult lens proliferation occurs almost exclusively in the equatorial region and although the central part of the lens epithelium exhibits very low mitotic activity, it was shown in experiments that cell in this area are also stem cells. There are three possible reasons for the generation of PCO: intraoperative factors (dependening on the amount of remaining cells in the capsular bag), intraocular lens factors, and interpersonal factor (patient-specific factors). Aim of this study is the generation of an in-vitro model of posterior capsule opacification. Therefore, the investigators will analyse the proliferative capacity of lens epithelial cells on the lens capsule, which is removed during cataract surgery, in a cell culture model. The investigators then compare the proliferative capacity between young and old patients, between both eyes of the same patient, and in different forms of cataract.

Interventions

PROCEDUREIn-vitro model

In-vitro model of posterior capsule opacification by culturing the lens capsule

Sponsors

Prim. Prof. Dr. Oliver Findl, MBA
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 105 Years
Healthy volunteers
No

Inclusion criteria

* Age-related cataract. * Patients in the age group of 21 years and older. * Patients with uncomplicated cataract. * Patients without any relevant systemic or ocular morbidity. * Patients with well dilating pupils. * Written informed consent prior to any study specific action.

Exclusion criteria

* Patients with complicated cataract. * Patients with big differences in LOCS scale between the two eyes. * Patients having corneal pathology. * Patients with any form of ocular inflammation. * Patients with glaucoma, retinal pathologies. * Patients with traumatic cataracts, subluxated and dislocated lens, prior h/o ocular surgery, pseudoexfoliation. * Any intraoperative complications like posterior capsule rupture. * In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age).

Design outcomes

Primary

MeasureTime frameDescription
Amount of proliferation of lens epithelial cells (LECs) in-vitro compared to in vivo in the same patient24 monthsProliferation of LECs in-vitro will be measured as area/mm2 and correlated with ratings of posterior capsular opacification in vivo using a scale from 0 to 10

Secondary

MeasureTime frameDescription
Amount of proliferation of LECs in-vitro in young and older patients24 monthsProliferation of LECs in-vitro will be measured as area/mm2 and compared between older and younger individuals
Amount of proliferation of LECs in-vitro between different forms of cataract24 monthsProliferation of LECs in-vitro will be measured as area/mm2 and compared between the different forms of cataract (cortical, nuclear, posterior subcapsular)

Countries

Austria

Contacts

Primary ContactAndreea Fisus, MD
office@viros.at01 91021-57564
Backup ContactManuel Ruiß, MSc.
office@viros.at01 91021-57564

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026